Cytheris announces publication of IL-7 HIV data in The Journal of Clinical Investigation.

Cytheris SA announced the publication of data from a multi-centre Phase I/IIa study designed to investigate the safety of Interleukin-7 (IL-7) therapy in chronically HIV-1 infected patients whose CD4 T cell counts remained low despite treatment with anti-retroviral-therapies (HAART). After 48 weeks, patients treated at the higher dose level showed a median increase in CD4 and CD8 T cell counts (cells/microliters) of 75% and 58%, respectively, from baseline levels. This study suggests that a new frontier in HIV therapy can be defined by the recovery and maintenance of a high level of CD4 T cells and that IL-7, with its potential ability to significantly impact naive and memory …